ArticleZoological research2018
King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates.
Article in Zoological research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Peptide OH-CATH30 Mitigates Cachexia-Induced Muscle Atrophy via Modulation of TLR4-Associated Inflammation.Journal of cachexia, sarcopenia and muscle · 2026Article
- Frog-Derived Peptide RL-RF10 Facilitates Gingival Repair and Regeneration Through the Integrin αvβ3/p38/Snail1 Axis.International dental journal · 2026Article
- Cathelicidin-like Peptide for ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Lowly Expressed Toxin Transcripts in Poorly Characterized Myanmar Russell's Viper Venom Gland.Biotech (Basel (Switzerland)) · 2025Article
- Threat and Control ofFoods (Basel, Switzerland) · 2025Review
- Nature's Arsenal: Uncovering Antibacterial Agents Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Dietary impact ofHeliyon · 2025Article
- An Update on the Therapeutic Potential of Antimicrobial Peptides againstPharmaceuticals (Basel, Switzerland) · 2023Review
- Assessing the Efficacy of PLGA-Loaded Antimicrobial Peptide OH-CATH30 Microspheres for the Treatment of Bacterial Keratitis: A Promising Approach.Biomolecules · 2023Article
- Hydrogen peroxide from L-amino acid oxidase of king cobra (Ophiophagus hannah) venom attenuates Pseudomonas biofilms.Scientific reports · 2023Article
- Past, Present, and Future of Naturally Occurring Antimicrobials Related to Snake Venoms.Animals : an open access journal from MDPI · 2023Review
- Review
- Bibliometric Analysis of Literature in Snake Venom-Related Research Worldwide (1933-2022).Animals : an open access journal from MDPI · 2022Article
- Imported Pet Reptiles and Their "Blind Passengers"-In-Depth Characterization of 80Microorganisms · 2022Article
- Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess.Frontiers in cellular and infection microbiology · 2022Review
- Article
- Article
- Review
- Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.Infection and drug resistance · 2021Review
- PEGylated Graphene Oxide Carried OH-CATH30 to Accelerate the Healing of Infected Skin Wounds.International journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic antimicrobial peptides (AMPs) are considered as important candidate therapeutic agents, which exert potent microbicidal properties against bacteria, fungi and some viruses. Based on our previous findings king cobra cathelicidin (OH-CATH) is a 34-amino acid peptide that exerts strong antibacterial and weak hemolytic activity. The aim of this research is to evaluate the efficacy of both OH-CATH30 and its analog D-OH-CATH30 against clinical isolates comparing with routinely utilized antibiotics in vitro. In this study, 584 clinical isolates were tested (spanning 2013-2016) and the efficacy of the candidate peptides and antibiotics were determined by a broth microdilution method according to the CLSI guidelines. Among the 584 clinical isolates, 85% were susceptible to OH-CATH30 and its analogs. Both L- and D-OH-CATH30 showed higher efficacy against (toward) Gram-positive bacteria and stronger antibacterial activity against nearly all Gram-negative bacteria tested compare with antibiotics. The highest bactericidal activity was detected against Acinetobacter spp., including multi-drug-resistant Acinetobacter baumannii (MRAB) and methicillin-resistant Staphylococcus aureus (MRSA). The overall efficacy of OH-CATH30 and its analogs was higher than that of the 9 routinely used antibiotics. OH-CATH30 is a promising candidate drug for the treatment of a wide variety of bacterial infections which are resistant to many routinely used antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.